Frontline Plc FRO 深 沪
已收盘 05-15 16:00:00 美东时间
36.66
-0.410
-1.11%
华盛通- 最 高37.035
- 今 开36.25
- 成交量 179.61万股
- 最 低 36.11
- 昨 收 37.07
- 总市值 81.61亿
- 52周最高 39.55
- 市盈率 静 21.53
- 换手率 0.81%
- 52周最低 14.665
- 委 比 55.56%
- 总股本 2.23亿
- 历史最高 41.67
- 量 比 0.67
- 振 幅 2.50%
- 历史最低 -4.84
- 每 手 1
- 风险率 6.99%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kura Oncology Reports First Quarter 2026 Financial Results
Kura Oncology reported first-quarter 2026 financial results, with $5.8 million in net product revenue for KOMZIFTI™ (ziftomenib) in its first full quarter of commercialization. The company achieved strong early momentum with 85 new patient starts, 157 total prescriptions, and over 93% payer coverage. Clinical advancements include ongoing trials across AML treatment settings, with multiple data readouts expected in 2026. Kura also highlighted its ...
05-12 20:02
Zebra FY26 Q1 net income slips 0.7% to $135 million; net sales rise 14.3% to $1.5 billion
Zebra FY26 Q1 net income slips 0.7% to $135 million; net sales rise 14.3% to $1.5 billion Zebra Technologies posted first-quarter net sales of USD 1.5 billion, up 14.3% year over year, while net income edged down 0.7% to USD 135 million. Diluted EPS rose 3.8% to USD 2.72, while gross margin widened
05-12 18:31
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
Syndax Pharmaceuticals highlighted the release of 12 Revuforj® (revumenib) abstracts for the EHA 2026 Congress, showcasing strong activity across acute leukemia treatment continuum and genetic subtypes. Key findings include compelling real-world outcomes, favorable tolerability, and encouraging results in post-transplant and combination therapies. Revumenib is FDA-approved for relapsed/refractory acute leukemia with KMT2A translocations or NPM1 m...
05-12 14:31
Medline Q1 2026 Earnings Call: Complete Transcript
Medline (NASDAQ:MDLN) released first-quarter financial results and hosted an ea...
05-06 22:52
Q1 2026 Trading Update
The Magnum Ice Cream Company reported a solid Q1 2026 with organic sales growth of 4.5%, driven by volume growth of 2.9% and price growth of 1.6%. Despite a 1.2% decline in reported revenue due to foreign exchange impacts, all regions contributed positively, with strong performances in the US, Europe, and AMEA. Acquisitions in India and Portugal were completed, and the productivity programme remains on track. The company reaffirms its full-year o...
04-30 06:00
AbbVie Q1 2026 Earnings Call: Complete Transcript
AbbVie (NYSE:ABBV) held its first-quarter earnings conference call on Wednesday...
04-29 22:47
美股大行评级 | 巴克莱大幅上调希捷科技、西部数据目标价！联合健康、霍顿房屋、盈透证券、奎斯特诊疗等获多家机构上调目标价
今日重点评级关注：Piper Sandler：维持MeiraGTx Holdings"超配"评级，目标价从26美元升至30美元；康托·菲茨杰拉德：维持MKS Inc."超配"评级，目标价从300美元升至400美元
04-23 12:35
BTIG Maintains Buy on Frontline, Raises Price Target to $45
BTIG analyst Gregory Lewis maintains Frontline (NYSE:FRO) with a Buy and raises the price target from $42 to $45.
04-22 19:29
Tanker firms DHT, Frontline, Nordic American downgraded at Evercore ISI
DHT Holdings (DHT) and Frontline (FRO) were downgraded at Evercore ISI on Tuesday to In-Line from Outperform, while Nordic American Tanker (NAT) was cut to Underperform from In-Line, noting spot rates...
04-22 04:52
